Exabis Library
Welcome to the e-CCO Library!
OP008: An innovative treatment for refractory perianal fistulas in Crohn's disease: local micro reinjection of autologous fat and adipose derived stromal vascular fraction
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP008: Detection of mucosal healing with a serum marker panel in adalimumab-treated patients with ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP008: Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP009: A combination of clinical, serological, and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP009: Gene-microbiome interactions underlying the onset and the clinical phenotypes of inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP010: Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP010: Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP010: Shallow whole-genome sequencing predicts the future cancer risk of low-grade dysplastic lesions arising in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP011: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study)
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP011: Integration of whole-exome sequencing and RNA sequencing of intestinal biopsies in inflammatory bowel disease identifies inflammation-dependent effects
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP012: Risk factors for colorectal neoplasia in ulcerative colitis: results from the largest and longest-running colonoscopic surveillance programme
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP013: Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP013: Evolution of corticosteroid use in Crohn’s disease patients between 1991 and 2014: results from the Dutch population-based Inflammatory Bowel Disease South Limburg cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP014: A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s disease refractory to anti-tumour necrosis factor α: UNITI-1
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM